This course offers a comprehensive update on the diagnosis and management of chronic spontaneous urticaria (CSU), a burdensome skin condition marked by recurrent hives and/or angioedema. Participants will explore evidence-based diagnostic approaches that reduce unnecessary testing, examine the clinical relevance of CSU endotypes and biomarkers, and apply guideline-based treatment algorithms. The course also highlights the evolving therapeutic landscape—including BTK inhibitors, IL-4/IL-13 inhibitors, and mast cell–targeted therapies—with emphasis on mechanism of action, clinical trial data, safety, and patient selection. Designed for allergists, dermatologists, and pediatric dermatologists, seeking to improve diagnostic accuracy, personalizing treatment, and effectively integrating emerging therapies into practice.
CME/CE Accreditation Information
The Type 2 inflammatory response plays a key role in several conditions, including atopic dermatitis, eosinophilic esophagitis, and asthma. While these diseases may present differently, they share a common underlying pathway, creating opportunities for more targeted and effective treatments. Pediatricians are well versed in managing these conditions, and recognizing their interconnections can help optimize patient care.
Exciting advancements in treatment, including biologics and other innovative therapies, offer new hope for patients with more severe forms of Type 2 inflammatory diseases. While these treatments are typically initiated by subspecialists, pediatricians play a vital role in identifying patients who may benefit from these options and guiding them through the referral process.
This program will provide valuable insights into recognizing comorbidities, making informed treatment decisions, and ensuring timely referrals so that patients receive therapies that address the root cause of their disease, not just the symptoms.
CME/CE Accreditation Information
Chronic spontaneous urticaria (CSU) is a prevalent, potentially debilitating disease that can prove challenging to manage successfully. Although antihistamines, anti-IgE monoclonal antibodies, and off-label suppressants can alleviate recurrent hives and angioedema, many patients with CSU are refractory to treatments comprising the standard of care. These limitations have spurred the development and examination of novel agents, such as BTK inhibitors, in patients with inadequately controlled disease. Through this three-part, small-group educational program, allergists, dermatologists, and other ancillary clinicians can learn how to more effectively navigate the CSU differential diagnosis, select the most appropriate therapies, and address more challenging management scenarios tied to treatment de-escalation. In doing so, healthcare providers can ensure that the rash of therapeutic developments in CSU are used to their fullest potential.
CME/CE Accreditation Information
